These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2005-001701-26||First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozol...||2008-02-28||due-trials|
|Not reported||2007-005022-71||Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer||2011-11-08||due-trials|
|Not reported||2008-001515-37||A prospective angiogenic imaging study with DCE-MRI and DCE-USI in patients with colorectal cancer and liver metastases receiving sunitinib in addition to 5-FU, folinic acid and irinotecan (FOLFIRI) ...||2010-07-12||due-trials|
|Completed, but no date Terminated||2009-010143-13||Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma||bad-data|
|Exempt||2010-018370-21||Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy||2014-09-25||not-yet-due|
|Reported results||2010-023688-16||An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC||2014-12-25||due-trials|
|Reported results||2011-003553-26||A single arm study in metastatic colorectal cancer patients treated with pharmacokinetically (PK) dose adjusted weekly or biweekly 5-fluorouracil (5-FU) regimes.||2014-09-17||due-trials|
|Completed, but no date Terminated||2011-005939-78||A prospective, open-label, multicenter, randomized phase II trial:||bad-data|
|Ongoing, reported early||2012-001415-23||A single arm Pharmacokinetic/Pharmacodynamic Study of Sunitinib and Pazopanib in Patients with Metastasized Renal Cell Carcinoma||not-yet-due|
|Ongoing||2013-005504-34||Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)||not-yet-due|
|Ongoing||2017-003780-35||Randomized phase II, open-label efficacy and safety study of second-line platinum-based chemotherapy followed by durvalumab (MEDI4736) plus tremelimumab versus platinum-based chemotherapy alone in pat...||not-yet-due|